Kaken gets some Asian rights to Brickell's BBI4000
Executive Summary
Brickell Biotech Inc. licensed Kaken Pharmaceutical Co. Ltd. exclusive rights to develop and commercialize its BBI4000 in Japan and certain other Asian countries.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice